Jinyu Kang

Statistics

Publications

Citations

H-Index

Active since

2008

Affiliations

AstraZeneca (United States)(Current)

AstraZeneca (United Kingdom)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Centre Hospitalier Universitaire de Besançon

Centre Hospitalier de l’Université de Montréal

Jinyu Kang is an author at AstraZeneca (United States) specializing in oncology, metastatic castration-resistant prostate cancer, and prostate cancer.

ORCID

Publications per year

2008–2025

Publications

Olaparib for Metastatic Castration-Resistant Prostate Cancer

Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi et al. · New England Journal of Medicine · 2020 · 2.2K citations · Full text

Medicine, Molecular Biology, Oncology +17

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

Maha Hussain, Joaquı́n Mateo, Karim Fizazi et al. · New England Journal of Medicine · 2020 · 766 citations · Full text

Medicine, Oncology, Pharmacology +17

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

Noel W. Clarke, Andrew J. Armstrong, Antoine Thiery-Vuillemin et al. · NEJM Evidence · 2022 · 394 citations

Medicine, Oncology, Pharmacology +17

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound Trial

Joaquı́n Mateo, Johann S. de Bono, Karim Fizazi et al. · Journal of Clinical Oncology · 2023 · 91 citations · Full text

Medicine, Oncology, Pharmacology +16

PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations

Maha Hussain, Joaquı́n Mateo, Karim Fizazi et al. · Annals of Oncology · 2019 · 82 citations

Medicine, Oncology, Pharmacology +17

1–5 of 19